


Help Documents (All users)	2
Pfizer Clinical Support Help Desk Call Tree Options	2
Impala 2.0 User Account Access (All users)	3
Impala 2.0 Study Roles and Account Types (All users)	3
Logging into Impala 2.0 (All users)	4
Subject Visit Date and Visit Completion Messages (All users)	
Screening (Site No Break Blind and Site Break Blind users)	6
Randomization (Site No Break Blind and Site Break Blind users)	11
Subject Visits for Cycle 1 Day 1 (Site No Break Blind and Site Break Blind users)	16
Subject Visits for Cycle X, Day 1 (Site No Break Blind and Site Break Blind)	25
Unplanned Visits (Site No Break Blind and Site Break Blind)	35
Subject Statuses (Site No Break Blind and Site Break Blind users)	41
Confirmation Reports and Requesting a Report (Site No Break Blind and Site Break Blind)	43
Replace Kit (assigned to Subject) (Site No Break Blind and Site Break Blind)	44
Change Kit Status (in Inventory) (Site No Break Blind and Site Break Blind)	48

\*\*Note - Receipt of Investigational Product has been split out as its own document. Please access the "Help Documents" link in Impala 2.0 to view this document.

# Help Documents (All users)



Please click on "Study Help" located in the top right corner of the Dashboard to access:

- This study specific Quick Reference Guide
- Impala 2.0 Data Correction Request Form
- Receipt of Investigational Product guide
  - Contains information on how to confirm Receipt of **Investigational Product**



# Pfizer Clinical Support Help Desk Call Tree Options



The Pfizer Clinical Support Help Desk can be reached at (+1) 877-433-2619

- For Account Provisioning (Exostar/SIP account set up)
  - Option 8: US CO Central Design, Pfizer Account Provisioning
- For Impala Support: -> Option 3 and select between the five options below:
  - Option 1: Impala Account request, Access modification/Password resets
  - Option 2: All other Impala issues
  - Option 3: Pfizer Learning Center Webpage (Impala Training Related Issues)
  - Option 4: Impala Kit Verify
  - Option 5: Shipment Notification Support



### **Outside of USA Toll Free Dialing information:**

- Please use the following link to find the correct calling code for the country in which you are currently located: https://www.business.att.com/collateral/access.html
- The Pfizer Clinical Support Help Desk is in the United States, so please locate the country you are dialing from. There will be no need for a PIN as the Help Desk number is a toll-free number.
  - Dial the AT&T Direct Toll-Free Access code provided + 877-433-2619 (Pfizer Clinical Support Help Desk)



- Translation services are always available when calling the Pfizer Clinical Support Help Desk.
  - o Please identify your preferred language and the Helpdesk analyst will conference in a translator.

**NOTE**: If you are unable to call the Pfizer Clinical Support Help Desk for any reason, an alternate contact method is by email: <a href="mailto:impala@pfizer.com">impala@pfizer.com</a>

• The Pfizer Clinical Support Help Desk email box is monitored 24/5 during the United States **business week.** However, the Pfizer Clinical Support Help Desk can be reached at **(+1) 877-433-2619** for any urgent issues anytime 24/7, including holidays.

# Impala 2.0 User Account Access (All users)



New Impala 2.0 account: Request IRT system access via the *Access Request for Pfizer Applications* link on the <u>Shared Investigator</u> <u>Platform (SIP)</u> Pfizer Sponsor Homepage. IRT System Training must be completed in the <u>Firecrest Portal</u> before access can be granted.

Impala 2.0 training is located in Firecrest under the Study Specific Portal.

# Already have an Impala 2.0 Account?

If you have already completed the Impala 2.0 Training previously for a different Impala 2.0 study; please contact the Pfizer Clinical Support Help Desk at (+1) 877-433-2619 to request to have this study added to your existing Impala 2.0 account.

# Impala 2.0 Study Roles and Account Types (All users)



When requesting an Impala 2.0 account it is critical that you identify your role on the study clearly to the Pfizer Clinical Support Help Desk. Failure to do so could result in improper access being granted.

Site Break Blind (PI, Sub-I, or Medical Designee)	Site No Break Blind (Site Coordinator)
Screen	Screen
Randomize	Randomize
Assign Drug	Assign Drug
Change Subject Status	Change Subject Status
Request Report	Request Report

SOP-PKG-00448-T02 V6.0 Quick Reference Guide
Pfizer Confidential Page **3** of **50** 




# Please take time to review the roles above and understand what your remit is for this study.

- If there is any uncertainty, please contact your site monitor prior to requesting your Impala 2.0 account.
- Only one account type should be requested per study.
- It is very important that account details are specific to an individual and **must not** be shared with anyone.


# Logging into Impala 2.0 (All users)

The Impala 2.0 link is available on the SIP Pfizer Sponsor Homepage and the SIP Study Workspace (appropriate permissions needed).

- Site staff may also access outside of SIP via the Exostar portal at https://secureaccess.exostar.com.
- If a user has permissions to more than one protocol or site, they will be presented with a list to choose from
- If only involved with one Protocol / Site, the page will only display one Protocol/Site
- Current Protocol / Site number is visible on every Impala 2.0 screen







SOP-PKG-00448-T02 V6.0 Quick Reference Guide
Page **5** of **50** 

#### **Out of Visit Window:**

- If visit is registered outside the protocol defined visit window [visit duration plus/minus interval] an Out of Visit Window message is displayed
  - Select **Yes** to continue registering visit transaction
  - Select **No** to halt visit transaction and return to subject summary

# **Out Of Visit Window** • Subject is outside next visit acceptable window. Do you wish to continue?

# **Screening (Site No Break Blind and Site Break Blind users)**


- Accessing the system at the time of each IRT visit is required.
- Impala 2.0 is the source of the Single Subject ID (SSID) number

Impaia 2.0 is the source of the single subject to (ssip) flumber.						
Visit Description	Function	To access, Click on:	Result in Impala 2.0			
Screening	Screen Subject	'Screen New Subject'  Screen New Subject  Or 'Add'  + Add	8-digit Screening Number (SSID) assigned			

SOP-PKG-00448-T02 V6.0 Page 6 of 50 Pfizer Clinical Support Help Desk: (+1) 877-433-2619

### C4891002 Quick Reference Guide

 From the Site Dashboard, click 'Screen New Subject'




• Or, from the 'Subjects' page list, click 'Add'




### **Collect Subject Data**

At Screening the system is collecting the following Subject Data:

- Gender
- Race
- Ethnicity
- Select the correct choices from the dropdown lists and click 'Next'.



Quick Reference Guide
Page 7 of 50



SOP-PKG-00448-T02 V6.0 Quick Reference Guide
Page **8** of **50** 

# C4891002 Quick Reference Guide 27 X **Visit Complete** Visit: Screen is completed for subject 10001036. Next IRT visit should be scheduled for 24-Apr-2023

Done

Quick Reference Guide Page **9** of **50** SOP-PKG-00448-T02 V6.0

Pfizer Clinical Support Help Desk: (+1) 877-433-2619

### C4891002 Quick Reference Guide

### **Screen Confirmation Report**

 Upon completion of the screening function, a Screening confirmation report will be sent to the email address associated to user's account.



Pfizer Clinical Support Help Desk: (+1) 877-433-2619

## C4891002 Screen Confirmation Report

Transaction Date: 27-Mar-2023 19:39:40 GMT

Study Code: C4891002 Site Code: 1000-1

Investigator: Joe Impala

Site Address: 1 Main Street Groton, CT 06498

United States

### Subject 10001036 Information

Subject Status: Screened

Screen Date: 27-Mar-2023

Visit ID: Screen

Visit Description: Screen

### **Subject Data Details**

Ethnicity: Not Hispanic or Latino(a) or of Spanish Origin

Race: Native Hawaiian or Other Pacific Islander

Gender: Male



### **Re-Screening**

Re-screening is permitted for this study, subject will be screened and new SSID assigned. Please ensure that the original SSID status is set to screen-fail in Impala 2.0.

# Randomization (Site No Break Blind and Site Break Blind users)

Accessing the system at the time of each IRT visit is required.

• Make certain you are scheduling your subjects in accordance with the protocol defined visit windows.


Before Enrollment/Randomization, ensure the initial shipment of Investigational Product has been received in Impala 2.0 (See Receipt of Investigational Product Guide in the Study Help Link).

Site personnel must not dispense Kit(s) to the subject until the Impala 2.0 Enrollment Confirmation/Subject Visit Confirmation Report has been received at the site. This will help ensure that the correct Kit(s) are dispensed to the subject.

If the Impala 2.0 Confirmation Report is not received in a timely manner the report can be regenerated. Please follow the instructions on how to regenerate confirmation reports under the "Confirmation Reports" section in this document.

Visit Description	Function	To access, Click on:	Result in Impala 2.0
Randomization	Randomize Subject	Subject ID (Subject Page) Randomization Visit Button Randomization	Randomization Number generated (recorded on CRF)

Quick Reference Guide Page 11 of 50 SOP-PKG-00448-T02 V6.0



SOP-PKG-00448-T02 V6.0 Quick Reference Guide
Pfizer Confidential Page 12 of 50

### **Enroll Subject Confirmation** 2 **Enroll Subject** The site user will be presented with the Enroll Subject confirmation screen The site must select 'Save' to proceed Please confirm that you wish to enroll the current subject: 10001036 To cancel the transaction click 'Cancel' When the subject has been successfully randomized/enrolled a message will display at the Cancel top of the screen displaying the rand number. This message disappears quickly. Subject 10001036 has been enrolled to randomization number 8006. **Statement Confirmation: Statement Confirmation** Completion of Randomization/Enrollment: Ensure Cycle 1 Day visit is logged within 3 days To complete Enroll Subject action, please read the following message(s): of randomization Click 'OK' on the Statement Confirmation · Please ensure the Cycle 1 Day 1 visit is logged within 3 days of randomization. screen to complete the randomization/enrollment. Cancel

No data is being collected by the site user but the 23 **Confirm Collected Data** system requires this message for Impala 2.0 configurations. No data collection needed at this time. Please click NEXT to continue. Click 'Next' to continue Cancel **Visit Completion message** 2 × **Visit Complete** After the completion of this visit, a Visit Completion dialog box will be displayed. Visit: Randomization is completed for subject 10001036. This information will include: o The completed Visit Description Click 'Done' to return to the Subject page.

Pfizer Clinical Support Help Desk: (+1) 877-433-2619

### C4891002 Quick Reference Guide

### **Enrollment Confirmation Report:**

The confirmation report will be sent to the email address associated to user's account.



Pfizer Clinical Support Help Desk: (+1) 877-433-2619

# C4891002 Enrollment Confirmation Report

Transaction Date: 27-Mar-2023 19:44:55 GMT

 Study Code:
 C4891002

 Site Code:
 1000-1

Investigator: Joe Impala

Site Address: 1 Main Street Groton, CT 06498

United States

Subject is Enrolled to Study

Visit Information:

Subject ID: 10001036 Subject Status: Active

Visit ID: Randomization
Visit Description: Randomization

Randomization Date: 27-Mar-2023

Randomization Number: 8006

Treatment Group: D [Dose Level 2 ARV-471 (PF-07850327) 200mg + palbociclib

75mg]



# Subject Visits for Cycle 1 Day 1 (Site No Break Blind and Site Break Blind users)

Accessing the system at the time of each IRT visit is required.

• Make certain you are scheduling your subjects in accordance with the protocol defined visit windows.

Site personnel must not dispense Kit(s) to the subject until the Impala 2.0 Subject Visit Confirmation Report has been received at the site. This will help ensure that the correct Kit(s) are dispensed to the subject.

• If the Impala 2.0 Subject Visit Confirmation Report is not received in a timely manner the report can be regenerated. Please follow the instructions on how to regenerate confirmation reports under the "Confirmation Reports" section in this document.

Visit Description	Function	To access, Click on:	
Cycle 1, Day 1	Assign Drug	Subject ID (Subject Page) Available <b>Visit Button</b>	
Visite Cycle 1 Day 1 Treatment	Treatment Group D		


Visit: Cycle 1, Day 1 Treat	D [ Dose Level 2 ARV-4/1 (PF-0/85032/) 200mg + palbociclib /5mg ]
Group B	Dispenses Palbo 75mg and ARV-471 100mg Bottle

SOP-PKG-00448-T02 V6.0 Quick Reference Guide
Pfizer Confidential Page **16** of **50** 



 Under the Upcoming Visits tab, Click the Day 1 button.

Note: the planned visit date for Cycle 1 day 1 is projected as 28 days from Randomization (because future cycles will follow this interval) but C1D1 should be planned for less than or equal to 3 Days from Randomization.



# Statement which shows at every drug assignment:

Beginning at Cycle 2, this statement explains drug assignment rules. Not relevant at C1D1 visits which is a fixed dispensation.


# **Statement Confirmation**

To complete Dispense Drug action, please read the following message(s):


- The following statements are applicable beginning at Cycle 2:
- DO NOT log the Day 1 visit if palbociclib dose is delayed. Instead, click CANCEL and log an Unplanned Visit to assign ARV-471 (PF-07850327).
- Once palbociclib is restarted, log the Day 1 visit to assign palbociclib and ARV-471 (PF-07850327).
- Select "None" if ARV-471 (PF-07850327)is not being dispensed
- Select "None" if permanently discontinuing any drug type (including palbociclib)

Cancel





SOP-PKG-00448-T02 V6.0 Quick Reference Guide Page **18** of **50** 



SOP-PKG-00448-T02 V6.0 Quick Reference Guide
Pfizer Confidential Page **19** of **50** 



# **Subject Visit Confirmation Report**

- Upon completion of each Visit, a Subject Visit
   Confirmation Report will be sent to the email address associated to your user's account.
- Follow your IP manual for instructions on verification of dispensation and IP reconciliation.



Pfizer Clinical Support Help Desk: (+1) 877-433-2619

# C4891002 Subject Visit Confirmation Report

Transaction Date: 27-Mar-2023 19:55:23 GMT

Study Code: C4891002 Site Address:

Site Code: 1000-1

Investigator: Joe Impala

ite Address: 1 Main Street Groton, CT 06498

United States

## Subject 10001036 Completed Visit

Subject Status: Active

Visit Date: 27-Mar-2023

Visit ID: Study Lead-in Cycle (1) Day 1

Visit Description: Day 1

Randomization Number: 8006

### Subject Dispense Kit

Visit ID	Dispensing Date	Kit	Kit Desc	Qty	Expiry Date
Study Lead-in Cycle (1) Day 1	1 27/Mar-2024 1 80022 1 078603271 100 mg		1	01-Jan-2050	
Study Lead-in Cycle (1) Day 1	27-Mar-2023	94023	Palbociclib 75 mg Bottle 23 ct (C489)	1	01-Jan-2050

SOP-PKG-00448-T02 V6.0




# Visit: Cycle 1, Day 1 Treatment Group C

Under the Upcoming Visits tab,
 Click the Day 1 button.

Note: the planned visit date for Cycle 1 day 1 is projected as 28 days from Randomization (because future cycles will follow this interval) but C1D1 should be planned for less than or equal to 3 Days from Randomization.

### Treatment Group C

C [ Dose Level 1 ARV-471 (PF-07850327) 200mg + palbociclib 100mg ] Dispenses Palbo 100mg Bottle and ARV-471 100mg Bottle



# Statement which shows at every drug assignment:

 Beginning at Cycle 2, this statement explains drug assignment rules. Not relevant at C1D1 visits which is a fixed dispensation.


# **Statement Confirmation**

To complete Dispense Drug action, please read the following message(s):

- The following statements are applicable beginning at Cycle 2:
- DO NOT log the Day 1 visit if palbociclib dose is delayed. Instead, click CANCEL and log an Unplanned Visit to assign ARV-471 (PF-07850327).
- Once palbociclib is restarted, log the Day 1 visit to assign palbociclib and ARV-471 (PF-07850327).
- · Select "None" if ARV-471 (PF-07850327)is not being dispensed
- · Select "None" if permanently discontinuing any drug type (including palbociclib)


Quick Reference Guide





SOP-PKG-00448-T02 V6.0 Quick Reference Guide
Pfizer Confidential Page 22 of 50





SOP-PKG-00448-T02 V6.0 Quick Reference Guide
Pfizer Confidential Page 23 of 50



# **Subject Visit Confirmation Report**

 Upon completion of each Visit, a Subject Visit Confirmation Report will be sent to the email address associated to your user's account.

Follow your IP manual for instructions on verification of dispensation and IP reconciliation.



Pfizer Clinical Support Help Desk: (+1) 877-433-2619

# C4891002 Subject Visit Confirmation Report

Transaction Date: 27-Apr-2023 21:02:42 GMT

Study Code: C4891002

1000-1

Investigator: Joe Impala

Site Code:

Site Address: 1 Ma

1 Main Street Groton, CT 06498

United States

### Subject 10001037 Completed Visit

Subject Status: Active

Visit Date: 27-Apr-2023

Visit ID: Study Lead-in Cycle (1) Day 1

Visit Description: Day 1

Randomization Number: 8007

### Subject Dispense Kit

Visit ID	Dispensing Date	Kit	Kit Desc	Qty	Expiry Date
Study Lead-in Cycle (1) Day 1	27-Apr-2023	80151	ARV-471 (PF- 07850327) 100 mg Bottle 60 ct	1	01-Jan-2050
Study Lead-in Cycle (1) Day 1	27-Apr-2023	96032	Palbociclib 100 mg Bottle 23 ct (C489)	1	01-Jan-2050



# Subject Visits for Cycle X, Day 1 (Site No Break Blind and Site Break Blind)


Accessing the system at the time of each IRT visit is required.

• Make certain you are scheduling your subjects in accordance with the protocol defined visit windows.


Site personnel must not dispense Kit(s) to the subject until the Impala 2.0 Subject Visit Confirmation Report has been received at the site. This will help ensure that the correct Kit(s) are dispensed to the subject.

• If the Impala 2.0 Subject Visit Confirmation Report is not received in a timely manner the report can be regenerated. Please follow the instructions on how to regenerate confirmation reports under the "Confirmation Reports" section in this document.

Visit Description	Function	To access, Click on:
Cycle V. Day 1	Assign Drug	Subject ID (Subject Page)
Cycle X, Day 1	Assign Drug	Available <b>Visit Button</b>




SOP-PKG-00448-T02 V6.0 Quick Reference Guide Page **25** of **50** 



Page **26** of **50** SOP-PKG-00448-T02 V6.0





SOP-PKG-00448-T02 V6.0 Quick Reference Guide
Pfizer Confidential Page **27** of **50** 



### **Treatment Group C**

C [ Dose Level 1 ARV-471 (PF-07850327) 200mg + palbociclib 100mg ]:

#### Palbociclib:


- Palbociclib 100 mg
   Bottle 23 ct
- Palbociclib 75 mg
   Bottle 23 ct
- None

### ARV-471 (PF-07850327)

- ARV-471 (PF-07850327) 100 mg
   Bottle 60 ct
- None


Note: 75mg Bottle of Palbociclib is offered for an approved dose reduction of Palbociclib.

Once subject is dose-reduced to 75mg Palbociclib, the choice of 100mg Palbociclib will not be offered at subsequent planned visits.



SOP-PKG-00448-T02 V6.0 Quick Reference Guide
Pfizer Confidential Page 28 of 50






SOP-PKG-00448-T02 V6.0 Quick Reference Guide Page **29** of **50** 



Click 'Confirm' on the Treatment Group C: **Dispense Confirmation** 2 **Dispense Confirmation** screen to complete the drug assignment. Please confirm that you wish to dispense drug to subject: 10001037 Cancel Treatment Group D: **Dispense Confirmation** Please confirm that you wish to dispense drug to subject: 10001036 Cancel Click 'Done' to Treatment Group C: complete the Drug 2 Dispensing complete for Visit: Day 1 Assignment. Please dispense the following kit(s) to 10001037 Discrete Numbered Kits Kit ID \$ Type \$ Kit Desc \$ Expiry Date \$ ARV-471 (PF-07850327) 100 mg 01-Jan-2050 80160 Blinded Bottle 60 ct Palbociclib 100 mg Bottle 23 ct 96034 Blinded 01-Jan-2050 (C489)Count: 2

SOP-PKG-00448-T02 V6.0 Quick Reference Guide
Pfizer Confidential Page **30** of **50** 





SOP-PKG-00448-T02 V6.0 Quick Reference Guide
Pfizer Confidential Page **31** of **50** 

CHOSTOOL QUICK NEIGHT CHICE GUIDE	•		
	Treatment Group D:		
	Visit Complete	∑×	
	Visit: <b>Day 1</b> is completed for subject 10001036.		
		Done	
<b>Subject Visit Confirmation</b>	Treatment Group C:		
Report			
Upon completion of each Visit,			
a Subject Visit Confirmation			
Report will be sent to the			
email address associated to your user's account.			
Follow your IP manual for			
instructions on verification of			
dispensation and IP			
reconciliation.			

SOP-PKG-00448-T02 V6.0 Quick Reference Guide
Pfizer Confidential Page **32** of **50** 

Pfizer Clinical Support Help Desk: (+1) 877-433-2619

C4891002 Quick Reference Guide



Pfizer Clinical Support Help Desk: (+1) 877-433-2619

### C4891002 Subject Visit Confirmation Report

Site Address:

Transaction Date: 27-Apr-2023 21:18:39 GMT

Study Code:

C4891002 1000-1 1 Main Street Groton, CT 06498

Site Code: Investigator:

Joe Impala

United States

Subject 10001037 Completed Visit

Subject Status: Active
Visit Date: 27-Apr-2023

Visit ID: Study Lead-in Cycle (2) Day 1

Visit Description: Day 1

Randomization Number: 8007

Subject Dispense Kit

Visit ID	Dispensing Date	Kit	Kit Desc	Qty	Expiry Date
Study Lead-in Cycle (2) Day 1	27-Apr-2023	80160	ARV-471 (PF- 07850327) 100 mg Bottle 60 ct	1	01-Jan-2050
Study Lead-in Cycle (2) Day 1	27-Apr-2023	96034	Palbociclib 100 mg Bottle 23 ct (C489)	1	01-Jan-2050

Treatment Group D:

Pfizer Clinical Support Help Desk: (+1) 877-433-2619

## C4891002 Quick Reference Guide



Pfizer Clinical Support Help Desk: (+1) 877-433-2619

# C4891002 Subject Visit Confirmation Report

Transaction Date: 27-Mar-2023 19:55:23 GMT

Study Code: C4891002

1000-1

Site Address:

1 Main Street Groton, CT 06498 United States

Site Code: Investigator:

Joe Impala

Subject 10001036 Completed Visit

Subject Status: Active

Visit Date: 27-Mar-2023

Visit ID: Study Lead-in Cycle (1) Day 1

Visit Description: Day 1

Randomization Number: 8006

### Subject Dispense Kit

Visit ID	Dispensing Date	Kit	Kit Desc	Qty	Expiry Date
Study Lead-in Cycle (1) Day 1	27-Mar-2023   80022   07850327) 100 mg		1	01-Jan-2050	
Study Lead-in Cycle (1) Day 1	27-Mar-2023	94023	Palbociclib 75 mg Bottle 23 ct (C489)	1	01-Jan-2050



# **Unplanned Visits (Site No Break Blind and Site Break Blind)**

Accessing the system at the time of each IRT visit is required.

• Make certain you are scheduling your subjects in accordance with the protocol defined visit windows.


Site personnel must not dispense Kit(s) to the subject until the Impala 2.0 Subject Visit Confirmation Report has been received at the site. This will help ensure that the correct Kit(s) are dispensed to the subject.

• If the Impala 2.0 Subject Visit Confirmation Report is not received in a timely manner the report can be regenerated. Please follow the instructions on how to regenerate confirmation reports under the "Confirmation Reports" section in this document.

Visit Description	Function	To access, Click on:
Unplanned Visit (1UPV)	Assign Davis	Subject ID (Subject Page)
2 UPV visits are allowed after each visit, as needed.	Assign Drug	Available Visit Button (Unplanned Visit)


**Unplanned Visits** have been configured for this study to:

- Assign ARV-471 (PF-07850327) if Day 1 of the next cycle of Palbociclib is delayed.
- Assign Palbociclib if dose needs to be reduced during a cycle.



SOP-PKG-00448-T02 V6.0 Quick Reference Guide
Pfizer Confidential Page **35** of **50** 





SOP-PKG-00448-T02 V6.0 Quick Reference Guide
Pfizer Confidential Page **36** of **50** 

Once subject is dose-reduced to 75mg Palbociclib, the choice of 100mg Palbociclib will not be offered at subsequent planned visits.

#### ARV-471 (PF-07850327)

- ARV-471 (PF-07850327) 100 mg Bottle 60 ct
- None


## **Treatment Group D**

D [ Dose Level 2 ARV-471 (PF-07850327) 200mg + palbociclib 75mg ]:


#### Palbociclib:

- Palbociclib 75 mg Bottle 23 ct
- None

Note: 75mg Bottle of Palbociclib is offered for an approved dose reduction of Palbociclib IF subject was increased to 100mg at Cycle 5 or later.




SOP-PKG-00448-T02 V6.0 Quick Reference Guide
Pfizer Confidential Page **37** of **50** 



SOP-PKG-00448-T02 V6.0 Quick Reference Guide
Pfizer Confidential Page **38** of **50** 





SOP-PKG-00448-T02 V6.0 Quick Reference Guide Page **39** of **50** 

#### C4891002 Quick Reference Guide



"INSUFFICENT SUPPLY" ERROR MESSAGE MAY RESULT IN A MANUAL DRUG ASSIGNMENT.

PLEASE UNDERSTAND THAT ANY MANUAL DRUG ASSIGNMENT CALL TO THE PFIZER CLINICAL SUPPORT HELP DESK MAY TAKE UP TO 1 HOUR TO COMPLETE.



Dispensing Failure: Insufficient Supply at Site.Please contact the Helpdesk.




### **Awareness Related to Kit Assignment Expiry Date**

- In rare circumstances the Pfizer Clinical Support Help Desk will manually assign a Kit(s) that is known to expire prior to the subject's next scheduled drug assignment visit.
  - Pfizer Clinical Support Help Desk will communicate this at the time of the manual assignment.
- Please consult the Impala 2.0 Subject Visit Confirmation Report generated at the time of the Manual Drug Assignment Visit Date to identify the Kit(s) that will expire prior to the subject's next scheduled drug assignment.
- Please communicate to the subject the expiration date and reinforce the need to return for additional supplies prior to that date.
  - Document the discussion with the subject in the source documents.
- Please contact Pfizer Clinical Support Help Desk to obtain additional or replacement Kit(s) assignments prior to the expiry recorded on the Impala 2.0 Subject Visit Confirmation Report.
- Please contact your monitor if you have any questions.






Register the status change in Impala 2.0 in as soon as it occurs to accurately predict drug supplies for your site.




### From the Subject Page click **Screen Fail**:



From the Subject Page click **Discontinue**:

SOP-PKG-00448-T02 V6.0 Quick Reference Guide
Pfizer Confidential Page **41** of **50** 





SOP-PKG-00448-T02 V6.0 Pfizer Confidential Page **42** of **50** 

C4891002 Quick Reference Guide		
	A Subject Discontinuation     Confirmation will be     generated	

Please contact the Pfizer Clinical Support Help Desk if your subject was screened in error or is incorrectly in a status of "Screen Failed" or "Discontinued Treatment". The Impala 2.0 system will only allow you to change the status once per subject.

# **Confirmation Reports and Requesting a Report (Site No Break Blind and Site Break Blind)**




Subject and Shipment specific reports will be automatically emailed to all site users, upon the completion of each function in Impala 2.0.



#### Prior Visits tab


Subject specific reports can be regenerated from the Subject page, Prior Visits tab

- Select the 'Prior Visits' tab
- Click the report icon associated to the Visit for the missing report
- Download, print, and/or save the report




#### Replace Kit (assigned to Subject) (Site No Break Blind and Site Break Blind) **Function** To access, Click on: Required to perform the function Result in Impala 2.0 Subject ID (Subject Page) Kit ID status changed Replace Kit Replace Kit Kit number (Replacement Kit dispensed for (Replace drug for subject) Select New Kit Status subject) Replace Kit The 'Replace Kit' function is used to replace **lost** or **damaged** kits that have been assigned to a subject.

### C4891002 Quick Reference Guide




SOP-PKG-00448-T02 V6.0 Quick Reference Guide
Pfizer Confidential Page **45** of **50** 




SOP-PKG-00448-T02 V6.0 Quick Reference Guide
Pfizer Confidential Page **46** of **50** 

### C4891002 Quick Reference Guide







SOP-PKG-00448-T02 V6.0 Quick Reference Guide
Pfizer Confidential Page **48** of **50** 

### C4891002 Quick Reference Guide

### **Site Kit Status Change Confirmation report:**

A Site Kit Status Change Confirmation report will be sent to the email address associated to your user's account.



Pfizer Clinical Support Help Desk: (+1) 877-433-2619

### C4891002 Site Kit Status Change Confirmation

Transaction Date: 14-Apr-2023 12:31:38 GMT

Study Code: Site Code: C4891002

1000-1

Investigator: Joe Impala

Site Address:

1 Main Street Groton, CT 06498 United States

#### Details of the kits with modified statuses

Kit ID	Old Status	New Status
68056	AVAILABLE	LOST

# **Document History**

Version #	Version Date	Author	Details	PPW Version #
1.0	28-Apr-2023	Kim Esposito	Original Version	1.0

SOP-PKG-00448-T02 V6.0 Quick Reference Guide
Pfizer Confidential Page **50** of **50** 

# **Document Approval Record**

**Document Name:** C4891002 Impala 2.0 Quick Reference Guide

**Document Title:** C4891002 Impala 2.0 Quick Reference Guide

Signed By:	Date(GMT)	Signing Capacity
Todd, Brian Kenneth	28-Apr-2023 17:30:25	Business Line Approver
Brennan, Christopher	02-May-2023 18:11:43	Data Verification
Valentino, Elizabeth	02-May-2023 19:21:29	Author Approval
Esposito, Kim M	02-May-2023 19:29:22	Author Approval